论文部分内容阅读
目的观察阿法骨化醇软胶囊联合雷洛昔芬治疗绝经后骨质疏松症的临床疗效。方法选取2015年1月—2016年1月南阳市骨科医院收治的绝经后妇女骨质疏松症患者102例,随机分为对照组和治疗组,每组各51例。对照组患者口服盐酸雷洛昔芬片,1片/次,1次/d。治疗组在对照组的基础上口服阿法骨化醇软胶囊,1粒/次,1次/d。两组患者均治疗6个月。评价治疗后两组患者临床疗效,同时比较治疗前后两组骨强度、骨代谢标记物含量和不良反应差异。结果治疗后,对照组和治疗组临床总有效率分别为82.35%、96.08%,两组比较差异具有统计学意义(P<0.05)。治疗后,两组患者骨密度和骨矿含量均明显升高(P<0.05);且治疗后治疗组骨强度指标明显高于对照组(P<0.05)。治疗后,两组患者I型胶原交联氨基端肽(NTXI)、I型胶原交联羧基端肽(CTXI)、抗酒石酸酸性磷酸酶5b(TRACP5b)和血骨钙素(BGP)含量均明显降低(P<0.05);且治疗组患者的骨代谢标记物含量明显低于对照组(P<0.05)。结论阿法骨化醇软胶囊联合雷洛昔芬治疗绝经后骨质疏松症疗效较好,具有一定的临床推广应用价值。
Objective To observe the clinical efficacy of alfacalolol soft capsule combined with raloxifene in the treatment of postmenopausal osteoporosis. Methods From January 2015 to January 2016, 102 cases of postmenopausal women with osteoporosis admitted to Nanyang Orthopedic Hospital were randomly divided into control group and treatment group, with 51 cases in each group. Control group patients oral raloxifene hydrochloride tablets, 1 / time, 1 time / d. The treatment group was treated with alfacalol soft capsule orally on the basis of the control group, once a day / once a day. Two groups of patients were treated for 6 months. The clinical efficacy of the two groups after treatment was evaluated, and the bone strength, the content of bone metabolism markers and the adverse reaction were compared between the two groups before and after treatment. Results After treatment, the total effective rates of the control group and the treatment group were 82.35% and 96.08%, respectively. There was significant difference between the two groups (P <0.05). After treatment, the bone mineral density and bone mineral content in both groups were significantly increased (P <0.05). After treatment, the bone strength of the treatment group was significantly higher than that of the control group (P <0.05). After treatment, the levels of type I collagen CTX, CTXI, TRACP5b and BGP were significantly higher in both groups (P <0.05). The content of bone metabolic markers in the treatment group was significantly lower than that in the control group (P <0.05). Conclusions Alfa calcifacin combined with raloxifene is effective in the treatment of postmenopausal osteoporosis and has certain value of clinical application.